EUCTR2013-004882-15-DE进行中（未招募）1 期
A multicentre randomized controlled trial evaluating the rate of sustained remission and the safety when stopping nucleos(t)ide analogue treatment in non-cirrhotic HBeAg-negative chronic Hepatitis B patients with long-term virologic response
niversität Leipzig0 个研究点目标入组 160 人开始时间: 2014年5月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients must meet ALL of the following criteria:
- •1.HBeAg negative chronic hepatitis B since the begin of antiviral treatment and HBV-DNA >2000 IU/ml at the begin of treatment
- •2.HBsAg positive at screening
- •3.Age = 18 years, male or female
- •4.Continuous nucleoside or nucleotide analogue therapy with either mono or combination therapy with adefovir dipivoxil (ADV), lamivudine (LMV), telbivudine (LdT), entecavir (ETV) or tenofovir disoproxil fumarate (TDF) for at least 4 years prior to screening.
- •Of note, as in previous observation the rates of HBsAg loss in HBeAg negative patients were comparable during treatment with all the mentioned drugs (Figure 3) we anticipate that the different drug regimes do not represent a factor influencing the response rates after treatment cessation in this trial. However, randomisation will be stratified with respect to the kind of previous therapy (see 8.1.1)
- •5.Documented undetectable HBV DNA level during treatment for at least 4 years prior to screening (quantification of HBV DNA must have been performed about every 4 to 8 months). Please note: In terms of this trial, we define undetectable” as below 1000 copies/mL (172 IU/mL). This comparatively high upper limit of HBV DNA levels was chosen for the definition of response to take into account that assays for HBV DNA quantification with different sensitivity are used in the participating centres.
- •6.Undetectable HBV DNA level at screening (analysed by central laboratory, Limbach and partners, Heidelberg)
- •7.Normal serum ALT levels < ULN (upper limit of normal) according to the local laboratory
- •8.Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 160
排除标准
- •Patients will be excluded for ANY ONE of the following reasons:
- •1.Compensated or decompensated liver cirrhosis
- •2.History of decompensated liver disease
- •3.Advanced fibrosis - defined either histologically by Scheuer score = stage 3 (within last year before screening) and/or liver stiffness = 10 kPa by elastography (Fibroscan®) or = 1.5 m/s by Acoustic Radiation Force Impulse (ARFI) (each within 6 months before screening)
- •4.Evidence of hepatocellular carcinoma (HCC)
- •5.HIV, HDV or HCV co-infection
- •6.Iatrogenic or disease-related immunosuppression (e.g. treatment with systemic glucocorticoids, TNFa-antibodies and other immunosuppressive drugs as well as chemotherapy or malignant disorders)
- •7.HBV associated extra hepatic manifestations (e.g. glomerulonephritis, panarteriitis nodosa, HBV-associated dermatosis)
- •8.Patients with Gilbert-Meulengracht syndrome can be included in the study if other potentially underlying liver diseases causing bilirubin elevation or hemolysis can be ruled out.
- •9.Significant alcohol consumption (> 30 g/day for women and > 50 g/day for men)
- •10. Patients who work in the medical field and have patient contact.
- •11.Pregnant or nursing women
- •12.Participation in any other interventional trial
- •13.Suspected lack of compliance
- •14.Fertile women (within two years of their last menstruation) without appropriate contraceptive measures (implanon, injections, oral contraceptives, intrauterine devices, partner with vasectomy) while participating in the trial (participants using a hormone-based method have to be informed of possible effects from the antiviral medication on contraception).
- •15.Patient is incapable to give informed consent
研究者
相似试验
已完成
不适用
A multicentre randomized controlled trial evaluating the rate of sustained remission and the safety when stopping nucleos(t)ide analogue treatment in non-cirrhotic HBeAg-negative chronic Hepatitis B patients with long-term virologic responseMedDRA - chronic hepatitis BB18Chronic viral hepatitisDRKS00006240niversität Leipzig166
招募中
不适用
The Coronary Artery Calcium Scoring in Women with Novel Cardiovascular Risk Factors Trial (CAC-Women Trial)Cardiovascular - Coronary heart diseasePublic Health - Health promotion/educationPublic Health - Epidemiologycardiovascular diseaseACTRN12621001738819The University of Sydney700
尚未招募
不适用
A Multi-Centre randomised controlled trial: Evaluation of Ovarian reserve following surgical treatment of endometriomas by excision or ablation.Ovarian endometriosisReproductive Health and Childbirth - Other surgeryACTRN12605000714684AGES42
进行中（未招募）
不适用
The Operative Rib Fixation (ORiF) studyRib fracturesInjury, Occupational Diseases, PoisoningFracture of ribISRCTN10777575ottingham University Hospitals NHS Trust467
已完成
不适用
A multicentre randomised controlled trial assessing the benefit of icodextrin solution on pelvic pain and quality of life in patients having surgery to adhesionsRespiratory: PainRespiratoryPainISRCTN77645288Department of Health (UK)250